Skip to content

Debt-to-assets at other companies

Incyte logo
IncyteINCY
0.0×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
0.2×+0.1×
UroGen Pharma logo
UroGen PharmaURGN
0.8×+0.3×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
2.4×+2.4×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
0.0×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
0.7×+0.2×

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s debt-to-assets?
Tyra Biosciences, Inc. (TYRA) reported debt-to-assets of 0× in Q1 2026.
How has Tyra Biosciences, Inc.'s debt-to-assets changed year-over-year?
Tyra Biosciences, Inc.'s debt-to-assets decreased by 22.5% year-over-year, from 0× to 0×.
What is the long-term trend for Tyra Biosciences, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s debt-to-assets has grown at a 17.0% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.